Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | KDM4A | O75164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 7/20 | 0.37 |
| ▸ | CA1 | P00915 | 7/20 | 0.37 |
| ▸ | CA2 | P00918 | 7/20 | 0.37 |
| ▸ | CA9 | Q16790 | 7/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | STK17B | O94768 | 1/20 | 0.35 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19794769 | 0.84 | KDM4A (0.40) | CACNA1HCACNA1BCACNA1CIGF1RAAK1 | |
| SCHEMBL29639462 | 0.84 | KDM4A (0.40) | CACNA1HCACNA1BCACNA1CIGF1RAAK1 | |
| SCHEMBL19794770 | 0.82 | TRPA1 (0.41) | CACNA1HCACNA1BCACNA1CTRPV1IGF1R | |
| SCHEMBL337994 | 0.82 | KDM4A (0.39) | IGF1RAAK1KDM4AL3MBTL1CA12 | |
| SCHEMBL29664091 | 0.77 | CACNA1H (0.46) | CACNA1HCACNA1BCACNA1CKDM4ALMNA | |
| SCHEMBL31706166 | 0.76 | CACNA1H (0.45) | CACNA1HCACNA1BCACNA1CAAK1KDM4A | |
| SCHEMBL10263975 | 0.75 | L3MBTL1 (0.50) | TRPV1L3MBTL1CA1CA2KDM4E | |
| SCHEMBL30884739 | 0.75 | RXFP1 (0.40) | AAK1CA1CA2LMNA | |
| SCHEMBL25317806 | 0.74 | AAK1 (0.42) | CACNA1HCACNA1BCACNA1CAAK1KDM4A | |
| SCHEMBL8247006 | 0.74 | LOXL2 (0.47) | CACNA1HCACNA1BCACNA1CKDM4AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034162-A1 | IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-01-30 | — | — | US | disclosed |
| US-12145944-B2 | Imidazopyrimidines as EED inhibitors and the use thereof | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-11-19 | — | — | US | disclosed |
| US-20220227778-A1 | IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-07-21 | — | — | US | disclosed |
| EP-3999510-A1 | IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF | The Regents Of The University Of Michigan (US) | 2022-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12145944-B2 | Imidazopyrimidines as EED inhibitors and the use thereof | EED, EEF1D, EEF1A1 | CACNA1H 4820/4885CACNA1B 4581/4885CACNA1C 4633/4885 |
| US-20250034162-A1 | IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF | EED, EEF1D, EEF1A1 | CACNA1H 4820/4885CACNA1B 4581/4885CACNA1C 4633/4885 |
| US-20220227778-A1 | IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF | EED, EEF1D, EEF1A1 | CACNA1H 4820/4885CACNA1B 4581/4885CACNA1C 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.